FDA advisers vote to support Paxlovid for COVID-19 treatment in high-risk adults

Mar 18, 2023, 1:06 PM | Updated: Mar 22, 2023, 7:33 am
PEMBROKE PINES, FLORIDA - JULY 07: In this photo illustration, Pfizer's Paxlovid is displayed on July 07, 2022 in Pembroke Pines, Florida. The US Food and Drug Administration revised the emergency use authorization for Paxlovid, Pfizer's Covid-19 antiviral treatment, to allow state-licensed pharmacists to prescribe the treatment to people. (Photo by Joe Raedle/Getty Images)
(Photo by Joe Raedle/Getty Images)
Originally Published: 16 MAR 23 06:35 ET
Updated: 17 MAR 23 11:01 ET

(CNN) — Advisers to the US Food and Drug Administration voted 16-1 on Thursday in support of full approval of Paxlovid, stating that the benefits outweigh the risks of the drug for treatment of mild to moderate Covid-19 in adults who are at high risk for severe disease, including hospitalization and death.

Before the antiviral medication is fully approved, the FDA — which typically follows the recommendations of its independent advisory committee — must conduct its own review. That’s expected to wrap up in May.

More than 8 million people in the US have received Paxlovid, a combination of the drugs nirmatrelvir and ritonavir, since it became available under emergency use authorization in December 2021.

“I’d say besides oxygen, Paxlovid has probably been the single most important tool in this epidemic, and it continues to be,” said Dr. Richard Murphy, chief of infectious diseases with the Veterans Affairs White River Junction Medical Center and a member of the FDA’s Antimicrobial Drugs Advisory Committee, who voted in support of approval at the meeting.

“We still have many groups that stand to benefit from the use of Paxlovid, including unvaccinated persons, undervaccinated persons, elderly, immunocompromised, and the other treatment options that we have have significant disadvantages,” he said.

A study published Friday in the medical journal JAMA Health Forum estimated that if Paxlovid uptake during the winter Omicron wave had been what it is now, nearly 5,000 deaths would have been prevented.

Data from phase 2 and 3 clinical trials supports the efficacy of Paxlovid regardless of Covid vaccination status or prior infection, the FDA said in documents released ahead of Thursday’s meeting. The agency also said it is reasonable to conclude, despite limited data, that Paxlovid is “likely to retain clinical efficacy” in high-risk adults with Covid infection caused by the Omicron variant of the coronavirus, as with earlier variants.

“I thought that the efficacy data were clear and convincing,” said Dr. Shankar Swaminathan, chief of infectious diseases at the University of Utah School of Medicine, who voted in support of approval Thursday. “I think that the fact that the drug has retained activity against various evolutionary strains of the virus is also reassuring and gives hope that this will continue to be the case going forward.”

Not linked to COVID-19 rebound

The FDA also concluded that Paxlovid is not associated with Covid-19 rebound, in which people test positive or see their symptoms return after they finish the five-day course of the drug.

The agency said it has reviewed data regarding rebound cases, which some users have reported since Paxlovid was authorized in 2021. Last year, both President Joe Biden and his former chief medical adviser, Dr. Anthony Fauci, reported rebound symptoms after taking Paxlovid.

However, based on clinical trial data, the FDA “did not identify a clear association between Paxlovid treatment and Covid-19 rebound.”

Covid rebound rates ranged from 10% to 16%, with no difference between people who took Paxlovid and those who took a placebo. This was also regardless of a person’s risk of severe disease with the Omicron variant compared with the Delta variant, according to clinical trial data reviewed by the FDA.

Overall, the agency said, the findings indicate that Covid-19 rebound may occur in a subset of infections as part of the natural progression and resolution of the disease.

Monitoring drug-drug interactions

No major safety concerns were identified in the clinical trial data, the FDA said. However, the agency has flagged 137 medications with Paxlovid drug-drug interactions (DDIs) that may lead to serious adverse reactions.

Paxlovid may keep the body from metabolizing certain drugs, leading to higher drug concentrations that can lead to serious or life-threatening reactions, according to an FDA Emergency Use Authorization Fact Sheet. Drugs that should not be taken with Paxlovid include some medications to treat conditions such as high cholesterol, gout, migraine, irregular heartbeat and benign prostatic hyperplasia.

According to the agency, more than 50% of Paxlovid-eligible patients may be on medication with a DDI at the time of Covid diagnosis.

“I would just emphasize that we underscore the importance of risk-mitigation to the prescriber, primary care physicians and other prescribers in terms of drug-drug interactions,” said FDA committee member Dr. David Hardy, an adjunct clinical professor at the Keck School of Medicine at the University of Southern California, who voted in support of approval. “That’s where I think we may get into trouble — or I can say where they can get into trouble — prescribing this medication without a good knowledge of what ritonavir does to other medications.”

The committee said the benefits of Paxlovid may not outweigh the risk of adverse drug reactions in all patients. For those at high risk of severe Covid-19, DDIs can be managed by holding the drug, adjusting the dose or increasing monitoring.

Clinical trials on the safety and efficacy of Paxlovid in children, people who are pregnant and those with weakened immune systems are ongoing.

™ & © 2023 Cable News Network, Inc., a Warner Bros. Discovery Company. All rights reserved.

We want to hear from you.

Have a story idea or tip? Send it to the KSL NewsRadio team here.

Today’s Top Stories


An off-duty pilot stepped in to help after a Southwest pilot became ill during a flight, the airlin...
Pete Muntean, CNN

Off-duty pilot on Southwest flight steps in to help after pilot suffers in-flight medical emergency

After safely returning to Las Vegas, a backup crew boarded and the flight continued to Columbus as planned.
2 days ago
Curt Gresseth

Mother tells of her escape from addiction and being homeless

A homeless mother describes her spiral into addiction and how she climbed out and is helping other homeless people today.
3 days ago
FILE - President Joe Biden speaks about health care and prescription drug costs at the University o...
Jeremy Diamond, CNN

White House to disband Covid-19 response team in May

The team was responsible for coordinating the nationwide rollout and distribution of vaccines, treatments and medical supplies.
3 days ago
Elizabeth Weiler

It’s time to re-enroll for Medicaid for the first time since before the pandemic

For the Beehive state beginning next month, for those applicable, Medicaid re-enrollment will be required.
5 days ago
Jason Sudeikis attends the Apple Original Series "Ted Lasso" Season 3 Red Carpet Premiere at Westwo...
Arlette Saenz, CNN

‘Ted Lasso’ cast will meet with President Biden for mental health discussion

A White House official said the meeting will focus on discussing "the importance of addressing your mental health to promote overall wellbeing."
6 days ago
Michelle Lee

Beating the Monday blues and the Sunday scaries

One expert said that Mondays have a cultural implication about "getting back to the grind" and that’s why it often impacts our mood.
7 days ago

Sponsored Articles

Cheerful young woman writing an assignment while sitting at desk between two classmates during clas...
BYU EMBA at the Marriott School of Business

Hear it Firsthand: 6 Students Share Their Executive MBA Experience at BYU’s Marriott School of Business

The Executive MBA program at BYU offers great opportunities. Hear experiences straight from students enrolled in the program.
Skier being towed by a rider on a horse. Skijoring....
Bear Lake Convention and Visitors Bureau

Looking for a new winter activity? Try skijoring in Bear Lake

Skijoring is when someone on skis is pulled by a horse, dog, animal, or motor vehicle. The driver leads the skiers through an obstacle course over jumps, hoops, and gates.
Banner with Cervical Cancer Awareness Realistic Ribbon...
Intermountain Health

Five common causes of Cervical Cancer – and what you can do to lower your risk

January is National Cervical Cancer Awareness month and cancer experts at Intermountain Health are working to educate women about cervical cancer.
Kid holding a cisco fish at winterfest...
Bear Lake Convention and Visitors Bureau

Get ready for fun at the 2023 Bear Lake Monster Winterfest

The Bear Lake Monster Winterfest is an annual weekend event jam-packed full of fun activities the whole family can enjoy.
happy friends with sparklers at christmas dinner...

15 easy Christmas dinner ideas

We’ve scoured the web for you and narrowed down a few of our favorite Christmas dinner ideas to make your planning easy.
Spicy Homemade Loaded Taters Tots...

5 Game Day Snacks for the Whole Family (with recipes!)

Try these game day snacks to make watching football at home with your family feel like a special occasion. 
FDA advisers vote to support Paxlovid for COVID-19 treatment in high-risk adults